Trial: 201708159

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)


III (Cancer Control)

Principal Investigator

Zhou, Amy

Disease Site

Myelodysplastic Syndrome (MDS); Other Hematopoietic

Learn more about this study at: